Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 16.02
- Piotroski Score 6.00
- Grade Outperform
- Symbol (CNS)
- Company Cohen & Steers, Inc.
- Price $95.75
- Changes Percentage (0.73%)
- Change $0.69
- Day Low $94.84
- Day High $97.51
- Year High $97.57
Cohen & Steers, Inc. is a publicly owned asset management holding company. Through its subsidiaries, the firm provides its services to institutional investors, including pension funds, endowments, and foundations. It manages separate client-focused equity, fixed income, multi-asset, and commodity portfolios through its subsidiaries. The firm launches and manages equity, fixed income, balanced, and multi-asset mutual funds through its subsidiaries. Through its subsidiaries, it also launches and manages hedge funds. The firm invests in public equity, fixed income, and commodity markets across the globe through its subsidiaries. Through its subsidiaries, it invests in companies operating in the real estate sector, including real estate investment trusts, infrastructure sector, and natural energy resources sector for its equity and fixed income investments. The firm also invests in preferred securities for its fixed income investments through its subsidiaries. Cohen & Steers, Inc. was founded in 1986 and is based in New York, with additional offices in London, United Kingdom; Central, Hong Kong; Tokyo, Japan; and Seattle, Washington.
- Last Earnings 08/01/2024
- Ex-Dividend for 5/16 Dividend 08/12/2024
- Dividend Payable 08/22/2024
- Today N/A
- Next Earnings (Estimated) 10/15/2024
- Fiscal Year End N/A
- Average Stock Price Target $73.00
- High Stock Price Target $73.00
- Low Stock Price Target $73.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $2.57
- Trailing P/E Ratio 26.68
- Forward P/E Ratio 26.68
- P/E Growth 26.68
- Net Income $129.05 M
Income Statement
Quarterly
Annual
Latest News of CNS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Sanofi gains exclusivity rights to Ventyx's CNS-penetrant drug in $27m deal
Sanofi secures exclusive rights to Ventyx Biosciences' CNS-penetrant candidate VTX3232 in a $27 million deal. This agreement grants Sanofi first negotiation rights for the potential neuroinflammatory ...
By Yahoo! Finance | 5 days ago -
Stocks Showing Improving Market Leadership: Reynolds Cnsmr Products Earns 84 RS Rating
IBD's RS Rating helps identify market leaders by comparing a stock's price movement against others. Look for stocks with RS Rating above 80 in early stages for potential winners. Focus on factors like...
By Investor's Business Daily | 3 weeks ago -
Reynolds Cnsmr Products Sees IBD RS Rating Improve To 71
Institutional support is crucial for stock performance. IBD's RS Rating measures a stock's technical performance over 52 weeks. Reynolds Consumer Products should show strength above 80 for potential g...
By Investor's Business Daily | 1 month ago
